Last updated: April 26, 2026
MULTIHANCE is the brand name for gadobenate dimeglumine, an MRI contrast agent. Commercial supply historically ties to the product’s original U.S. manufacturer and packager network tied to the brand’s rights holder.
Which companies supply MULTIHANCE in the U.S.?
MULTIHANCE (gadobenate dimeglumine) is manufactured and supplied in the U.S. under the brand by Bracco. The U.S. product is marketed under the Bracco brand umbrella, and the drug product supply chain is aligned to Bracco’s manufacturing and packaging responsibilities for this presentation. (See FDA labeling listing.)
U.S. brand labeling (marketed product)
| Item |
Value |
| Brand |
MULTIHANCE |
| Active ingredient |
gadobenate dimeglumine |
| Dosage form |
Injection |
| Market authorization (FDA label) |
Bracco-branded labeling for the U.S. |
FDA label records show the product name and active ingredient as gadobenate dimeglumine injection and keep the U.S. labeling tied to the Bracco brand platform. (FDA Drug Labeling entry for MULTIHANCE.) [1]
What is the supplier role breakdown (manufacturer vs. distributor)?
MULTIHANCE supply typically follows the standard pharmaceutical model:
- Manufacturer/packager: creates and packages the finished injectable product.
- Marketing authorization holder / brand owner: controls U.S. product labeling, distribution arrangements, and regulatory compliance for the marketed product.
- Wholesale/distribution: ships finished product to providers and wholesalers through the brand’s distribution channels.
For MULTIHANCE, the controlling upstream supplier role for the branded product is the Bracco platform referenced in FDA labeling for the product. [1]
What product configurations drive different supply SKUs?
MULTIHANCE is sold in unit-dose presentations, and supplier responsibilities can shift at the packaging SKU level (bottle size, carton configuration), while the underlying manufacturer platform stays linked to the label holder.
The FDA label documents the product as gadobenate dimeglumine injection and supports the marketed product identity used by distributors and providers. [1]
How does the generic/ANDA landscape affect “supplier” answers?
For a branded contrast agent like MULTIHANCE:
- When an FDA-approved generic/“follow-on” product exists, suppliers change at the ANDA product level.
- If a reference product remains dominant, “supplier” questions map to the brand holder’s finished-product manufacturing/packaging.
The authoritative anchor for “who supplies MULTIHANCE” in a business sense is the branded product labeling and the listed manufacturer/labeling holder in U.S. regulatory records. [1]
Where suppliers show up in practice (procurement-facing signals)?
Procurement teams usually identify the supplier through:
- FDA label and NDC-linked product identity
- Contracted distributor listings for the NDC
- Hospital group purchasing documentation tied to NDC and brand
MULTIHANCE’s procurement identity is directly tied to its FDA-labeled product and active ingredient. [1]
Key Takeaways
- MULTIHANCE is a Bracco-branded gadobenate dimeglumine injection in the U.S., so the commercial supplier for the branded product is the Bracco product platform tied to the U.S. FDA-labeled entry. [1]
- Supplier “roles” split into manufacturer/packager, brand holder, and distributors; for MULTIHANCE the controlling branded supplier identity maps to Bracco via FDA labeling. [1]
FAQs
1) Who is the supplier of MULTIHANCE in the U.S.?
The branded U.S. supply is tied to Bracco as the labeling/brand platform holder for MULTIHANCE (gadobenate dimeglumine) injection. [1]
2) Is MULTIHANCE manufactured by the same company that markets it?
For the branded product, U.S. regulatory labeling ties the marketed product to the Bracco platform. [1]
3) What is the active ingredient in MULTIHANCE?
gadobenate dimeglumine. [1]
4) Why do supplier listings vary across hospitals?
Hospital procurement uses NDC-level product identity, contract distributors, and packaging SKUs; the regulatory anchor remains the labeled branded product identity. [1]
5) Can suppliers change if a follow-on product enters the market?
Yes. If an alternate FDA-approved product is procured instead of the branded NDC, the supplier shifts at the product/NDC level; branded MULTIHANCE supply stays tied to the labeled Bracco platform. [1]
References
[1] U.S. Food and Drug Administration. (n.d.). MULTIHANCE (gadobenate dimeglumine) injection, for intravenous use: Labeling. FDA Drug Labeling. https://www.accessdata.fda.gov/
